Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorviqua in Relapsed ALK-positive Lymphoma After ALK Inhibitors
2025-520788-42-00Phase 2Completed
- Sponsor
- University of Milano-Bicocca
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lorlatinib in anaplastic large cell lymphoma (ALCL), sponsored by University of Milano-Bicocca. Primary endpoint: overall response rate. Started Jan 2025; status: completed.
02
Drugs
lorlatinib
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on 2025-520788-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520788-42-00.